NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Parkinson's disease (PD) is the second most common prevalent neurodegenerative disease. Recent studies revealed that dysregulation of copper homeostasis was associated with the progression of PD. However, safe and efficient therapeutic drugs were deficient. Our study first demonstrated that Artesunate (AS) targeted on astrocyte to attenuate 6-OHDA-induced dopamine (DA) neurotoxicity. Furtherly, using HuProt™ 20 K human proteome microarray and SPR analysis, it was demonstrated and validated that metallothionein 2 A (MT2A) was a direct AS-binding protein, which high-expressed in astrocyte and up-regulated by AS. In addition, AS decreased intracellular Cu2+ level and regulated the expression of cuproptosis-associated proteins, such as FDX1, CTR1 and Lip-DLAT. Finally, rescue experiments indicated that AS-mediated DA neuroprotection, Cu2+ reduction and anti-cuproptosis effects were eliminated by MT2A knockdown and MT2A-Lys-31 was a key functional site. Taken together, AS provided neuroprotection against PD via up-regulation of astrocyte MT2A expression, which further decreased intracellular Cu2+ level and improved DA neuronal cuproptosis. These findings provide a valuable resource for AS-binding proteins and present a potential application of AS on PD treatment.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.